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Daniel E. Furst2, Michael D. Roth2, Oliver Distler3 and Donald P. Tashkin2
Abstract
Objective: This study aimed to assess the minimal clinically important differences (MCIDs) for the modified Rodnan
skin score (mRSS) using combined data from the Scleroderma Lung Studies (I and II).
Methods: MCID estimates for the mRSS at 12months were calculated using three anchors: change in scores on the
Health Assessment Questionnaire- Disability Index from baseline to 12months, change in scores on the Patient Global
Assessment from baseline to 12months, and answer at 12month for the Short Form-36 health transition question
“Compared to one year ago, how would you rate your health in general now?” We determined the mRSS MCID estimates
for all participants and for those with diffuse cutaneous systemic sclerosis (dcSSc). We then assessed associations between
MCID estimates of mRSS improvement and patient-reported outcomes, using Student’s t test to compare the mean
differences in patient outcomes between those who met the MCID improvement criteria versus those who did not meet
the improvement criteria.
Results: The mean (SD) mRSS at baseline was 14.75 (10.72) for all participants and 20.93 (9.61) for those with dcSSc.
The MCID estimate for mRSS improvement at 12months ranged from 3 to 4 units for the overall group (improvement
of 20–27% from baseline) and was 5 units for those with dcSSc (improvement of 24% from baseline). Those who met
the mRSS MCID improvement criteria had statistically significant improvements in scores on the Short Form-36 Physical
Component Summary, the Transition Dyspnea Index, and joint contractures at 12months.
Conclusion: MCID estimates for the mRSS were 3–4 units for all participants and 5 units for those with dcSSc. These
findings are consistent with previously reported MCID estimates for systemic sclerosis.
Keywords: Interstitial lung disease, Systemic sclerosis, Minimal clinically important difference, Skin thickness,
Scleroderma, Modified Rodnan skin score
Introduction
Systemic sclerosis (SSc; scleroderma) is a multiorgan dis-
ease with a complex interplay of diverse pathological
processes involving inflammation, fibrosis, and vasculop-
athy. While organ involvement in SSc varies, skin in-
volvement is almost universal in SSc [1]. The modified
Rodnan skin score (mRSS), a measure of skin thickness,
is the primary outcome measure in the majority of clin-
ical trials of diffuse cutaneous SSc (dcSSc). Measurement
of skin thickness is used as surrogate measure of disease
severity and mortality in patients with dcSSc. Specific-
ally, an increase in skin thickening is associated with in-
volvement of internal organs and increased mortality [1].
It is generally accepted that the mRSS tends to worsen
in the early part of the disease and to improve in late
disease, although the time of peak involvement is poorly
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defined. The mRSS is feasible, reliable, valid, and sensi-
tive to change in multicenter clinical trials [2].
To interpret change in the mRSS within a group of par-
ticipants with SSc over time, or to interpret differences in
the mRSS between two groups, it is important to first de-
fine whether the change or difference is clinically meaning-
ful. The minimal clinically important difference (MCID) is
defined as the smallest difference in a measure or instru-
ment that is considered to be “worthwhile or important” to
patients [3]. For clinicians, the MCID helps guide treat-
ment. While there are several methods for calculating the
MCID, estimating the MCID using an external anchor is
often preferred over other methods [4]. Khanna et al. [5]
previously published MCID estimates for the mRSS using
data from the D-penicillamine trial, which involved a cohort
of patients with early dcSSc. They found that an improve-
ment of 3.2–5.3 units for the mRSS were the MCID esti-
mates. However, they used physician assessment of change
over time as the anchor to determine the MCID estimates;
it is preferred that this information comes directly from pa-
tients [4]. Thus, in this article, we analyzed data from two
clinical trials in SSc-related interstitial lung disease—the
Scleroderma Lung Studies I and II (SLS-I and SLS-II)—to
calculate the MCID estimates for the mRSS using
patient-reported anchors from participants with SSc.
Methods
Participants
All participants with any outcome data in SLS-I and
SLS-II were evaluated in this post-hoc analysis. The
study protocols for both SLS-I and SLS-II were ap-
proved by the local Institutional Review Boards, and
written informed consent was obtained from all partici-
pants. The trial designs for both SLS-I and SLS-II have
been published elsewhere [6, 7]. Briefly, participants
meeting the 1980 SSc classification criteria were in-
cluded. Participants in SLS-I were randomized to 1 year
of oral placebo or oral cyclophosphamide, with the pri-
mary endpoint being change in FVC percent predicted
(FVC%) at 1 year. Participants in SLS-II were random-
ized to 2 years of mycophenolate mofetil or 1 year of
oral cyclophosphamide followed by 1 year of placebo.
The primary endpoint for SLS-II was the course of the
FVC% from baseline to 24months using a joint model,
which examined the repeated measurements of FVC%.
The mRSS was captured as a secondary outcome meas-
ure in both trials [8] and was assessed by experienced
rheumatologists at Scleroderma Centers for Excellence
throughout the trials. We did not perform mRSS training
sessions before each trial.
Methods and procedures
Participants’ clinical data included age, gender, race, dis-
ease duration (from first non-Raynaud’s symptom
attributable to SSc), skin subtype of SSc (dcSSc or lim-
ited cutaneous SSc (lcSSc)), presence of tendon friction
rubs (captured as yes or no at baseline and month 12),
presence of small and large joint contractures (captured
as yes or no at baseline and month 12), and the mRSS.
In both studies, the patient-reported outcome measures
included the Mahler Baseline and Transition Dyspnea
Indexes (BDI and TDI), the Health Assessment Ques-
tionnaire (HAQ-DI), the Medical Outcomes Short
Form-36 (SF-36), and the Patient Global Assessment of
Disease Activity (PtGA) [9].
The Mahler Baseline and Transition Dyspnea Indexes
(BDI and TDI) [10] measured patient dyspnea. The BDI
measured patient dyspnea at baseline, and the TDI mea-
sured their change from baseline to 12months. Scores
ranged from − 3 to + 3 for three domains, for a sum ran-
ging between − 9 and + 9. Higher positive scores con-
noted less dyspnea (BDI) or an improvement in dyspnea
(TDI). While both the BDI and the TDI were assessed
using paper questionnaires in SLS-I, both indices were
assessed using a self-administered, computer-generated
format in SLS-II.
The Health Assessment Questionnaire (HAQ-DI) is a
20-item questionnaire assessing patients’ functional dis-
ability in eight domains. Scores ranged from 0.0 (best) to
3.0 (worst) [11]. It has been fully validated in SSc [12].
The Medical Outcomes Short Form-36 (SF-36) version 2
is a self-administered survey assessing patients’ generic
health-related quality of life. It generated a physical compo-
nent summary and a mental component summary [13] and
was scored on a t-score metric with a US population mean
of 50 (SD 10); a higher score denoted better health-related
quality of life. One item is a health transition question and
asked the patient whether their health had got better or
worse, as described in more detail in the following. The
SF-36 has been previously validated in SSc [14].
Statistical analysis
Summary statistics were calculated for all demographic
and clinical variables. Continuous variables are reported
as mean and standard deviation (SD), and frequencies
are reported for categorical variables.
Anchors to assess the MCID
To determine the MCID, we used three anchors directly
from participants: the health transition question from
the SF-36 answered at 12 months, the change in their
HAQ-DI score from baseline to 12 months, and the
change in their PtGA score from baseline to 12
month visit. We chose these anchors based on their rela-
tionships to the mRSS in previous studies [15] and be-
cause all of this information is provided directly by the
patient. Additionally, experts recommend multiple an-
chors to get robust estimates [4]. The SF-36 health
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transition question asks the patient: “Compared to one
year ago, how would you rate your health in general
now?” We used the “somewhat better” and “somewhat
worse” responses as the anchors for calculating the
MCID [16–18]. For the HAQ-DI, we chose a previously
published MCID estimate of 0.14 units for improvement
in SSc [5] and other arthritides [0.22], and we used an
arbitrary cutoff point of 0.48 because large improve-
ments in the HAQ-DI score may be greater than the
MCID. For the PtGA, we used a cutoff point of 20 units
(0–100 units) as the MCID, and we used an arbitrary
cutoff point of 50 units as a change that is greater than
the MCID.
We assessed the appropriateness of the anchors by
calculating Spearman correlations between the an-
chors (changes in HAQ-DI scores, changes in PtGA
scores, and the SF-36 health transition answer at 12
months) and changes in the mRSS from baseline to 12
months. Generally, a correlation coefficient of ≥ 0.30 is
considered acceptable [4, 19]. If we did not achieve
this threshold, we considered p < 0.05 as an acceptable
alternative. We also sought to determine whether the
MCID estimates for changes in the mRSS were associ-
ated with changes in several patient-reported out-
comes (i.e., the SF-36 Physical and Mental Component
Summary Scores and the TDI), and changes in phys-
ical examination (improvement in tendon friction rubs
and joint contractures) due to their relationship with
mRSS [20].
Student’s t tests or chi-square tests were used to com-
pare the mean difference in patient-reported outcomes
or in percent difference between those who had im-
proved mRSS as defined by the MCID estimates versus
those whose mRSS scores did not improve as defined by
the MCID. We calculated the effect size as the mean
change in the mRSS divided by the SD at baseline. p <
0.05 was considered statistically significant and no ad-
justment was made for multiple testing.
Results
Baseline characteristics and changes in mRSS and patient-
reported outcomes
We evaluated data from 300 participants in SLS-I and
SLS-II combined (158 participants in SLS-I and 142 par-
ticipants in SLS-II; Table 1). The mean (SD) age of the
pooled cohort was 50.3 (11.3) years, mean (SD) disease
duration was 2.9 (2.0) years, mean (SD) FVC% at baseline
was 67.4% (10.8%), and 59% of the participants had dcSSc
in both trials (Table 1). While both studies were compar-
able in most baseline characteristics, those in SLS-II were
older (p = 0.004), had shorter mean disease duration (p =
0.01), and had less baseline dyspnea as assessed by the
BDI (data not shown; 7.2 vs 5.7, p < 0.001).
Table 1 Baseline demographics for all participants
Variable Category Overall Diffuse SSc Limited SSc p value
N Mean (SD) N Mean (SD) N Mean (SD)
Age, mean (SD) (years) 300 50.3 (11.3) 177 49.3 (11.5) 123 51.6 (10.9) 0.08
Disease duration (years) 297 2.9 (2.0) 176 2.9 (1.9) 121 2.9 (2.1) 0.79
Gender, N (%) Male 84 (28%) 54 (31%) 30 (24%) 0.25
Female 216 (72%) 123 (69%) 93 (76%)
SSc type, N (%) Diffuse 177 (59%) 177 (100%) 0 (0%)
Limited 123 (41%) 0 (0%) 123 (100%)
Race, N (%) Caucasian 177 (59%) 101 (57%) 76 (62%) 0.12
Black 58 (19%) 41 (23%) 17 (14%)
Other 65 (22%) 35 (20%) 30 (24%)
mRSS—baseline, mean (SD) Overall 300 14.75 (10.72) 177 20.93 (9.61) 123 5.85 (3.61) < 0.0001
mRSS—12 months, mean (SD) 244 11.90 (9.91) 146 16.10 (10.41) 98 5.64 (4.17) < 0.0001
Patient Global Assessment—baseline, mean (SD) 249 39.0 (26.9) 145 43.5 (26.6) 104 32.7 (26.1) 0.002
HAQ-DI--baseline, mean (SD) 299 0.78 (0.67) 177 0.99 (0.72) 122 0.48 (0.49) < 0.0001
BDI,--baseline mean (SD) 287 6.4 (2.2) 171 6.4 (2.2) 116 6.4 (2.2) 0.97
SF-36 PCS--baseline, mean (SD) 285 34.7 (10.5) 169 32.9 (10.6) 116 37.4 (9.8) < 0.0001
SF-36 MC--baselineS, mean (SD) 285 49.5 (9.9) 169 48.7 (10.0) 116 50.6 (9.5) 0.11
Joint contractures present at baseline, N (%) 143 (48%) 111 (63%) 32 (26%) < 0.0001
Tendon friction rubs present at baseline, N (%) 36 (13%) 34 (20%) 2 (2%) < 0.0001
BDI Baseline Dyspnea Index, HAQ-DI Health Assessment Questionnaire Disability Index, mRSS modified Rodnan Skin Score, SD standard deviation, SF-36 MCS Short
Form-36 Mental Component Summary, SF-36 PCS Short Form-36 Physical Component Summary, SSc systemic sclerosis
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The mean (SD) mRSS at baseline for all participants
was 14.75 (10.72), but the mRSS was higher for those
with dcSSc and lower for those with lcSSc as expected
(Table 1). The change in mRSS was − 2.84 (5.91) in the
overall group, − 4.49 (6.75) in dcSSc participants, and −
0.37 (3.00) in lcSSc participants.
Correlation coefficients to assess the appropriateness of
MCID anchors
For our MCID analysis, the correlation coefficients be-
tween the anchors (SF-36 health transition at 12 month
period and changes in HAQ-DI and PtGA from baseline
to 12months) and the change in the mRSS from base-
line to 12months did not meet the 0.30 threshold
(Table 2). However, the correlations for the overall group
were statistically significant, thus meeting our alternative
criteria and indicating that the anchors are acceptable.
To better understand this, we calculated the correlations
separately for those participants with dcSSc and those
with lcSSc. For those participants with dcSSc, the coeffi-
cients were also below the 0.30 threshold, but all three
correlation coefficients were statistically significant. For
those participants with lcSSc, the coefficients were very
small and not statistically significant.
mRSS MCID estimates for reported improvement in the
overall group
We provide unadjusted mRSS MCID estimates for both
improvement and no change in all three anchors (Ta-
bles 3, 4, and 5). For the SF-36 health transition ques-
tion, the mean mRSS MCID estimate for reported
improvement (defined as answering “somewhat im-
proved”) was − 2.86 with an effect size of 0.27. This esti-
mate was similar to the group that reported no change
for the question, which had an estimate of 2.72 with an
effect size of 0.25 (Table 3). Using the HAQ-DI cutoff
points described earlier, the mRSS MCID estimate for
HAQ-DI improvement was − 3.56 with an effect size of
0.33, and this was numerically larger than the HAQ-DI
no change group (mean change of − 2.55 and effect size
of 0.24; Table 4). Using the PtGA cutoff points described
earlier, the mRSS MCID estimate for PtGA improvement
was − 4.06 with an effect size of 0.38, and this was nu-
merically larger than the PtGA no change group (mean
change of − 2.94 and effect size of 0.27; Table 5).
mRSS MCID estimates for reported improvement in those
with dcSSc
For those participants with dcSSc, using the SF-36
health transition question, the mean mRSS MCID esti-
mate for those who reported improvement was − 4.70
with an effect size of 0.49. This was similar to the group
reporting no change, which had an estimate of − 4.61
with an effect size of 0.48 (Table 3). Using the HAQ-DI,
Table 2 Spearman correlation coefficients between change in
mRSS and the three patient-reported anchors
Overall Diffuse SSc Limited SSc
Health transition 0.19 (p = 0.007) 0.21 (p = 0.02) − 0.03 (p = 0.81)
n = 187 n = 115 n = 72
PtGA 0.21 (p = 0.004) 0.20 (p = 0.02) 0.11 (p = 0.33)
n = 195 n = 118 n = 77
HAQ-DI 0.24 (p = 0.0002) 0.26 (p = 0.001) 0.10 (p = 0.34)
n = 243 n = 146 n = 97
HAQ-DI Health Assessment Questionnaire Disability Index, mRSS modified
Rodnan Skin Score, PtGA Patient Global Assessment, SSc systemic sclerosis
Table 3 Estimation of MCID estimates in mRSS using SF-36
health transition anchor for all participants
Change in mRSS by
level of anchors—
SF-36 health transition
item
N Unadjusted mean Effect
sizeMean 95%
LCL
95%
UCL
Overall
Much better (1) 50 −
5.64
−
7.31
−
3.97
− 0.53
Somewhat better (2) (MCID
estimate for improvement)
35 −
2.86
−
4.94
−
0.78
− 0.27
Same (3) 67 −
2.72
−
3.96
−
1.48
− 0.25
Somewhat worse (4) 32 −
1.66
−
4.04
0.73 − 0.15
Much worse (5) 3 −
4.67
−
20.64
11.3 − 0.44
Diffuse SSc
Much better (1) 35 −
7.66
−
9.64
−
5.67
− 0.80
Somewhat better (2) (MCID
estimate for improvement)
23 −
4.70
−
7.38
−
2.01
− 0.49
Same (3) 36 −
4.61
−
6.56
−
2.66
− 0.48
Somewhat worse (4) 20 −
2.25
−
6.12
1.62 − 0.23
Much worse (5) 1 −
12.00
Limited SSc
Much better (1) 15 −
0.93
−
2.28
0.41 − 0.26
Somewhat better (2) (MCID
estimate for improvement)
12 0.67 −
1.82
3.15 0.19
Same (3) 31 −
0.52
−
1.61
0.58 − 0.14
Somewhat worse (4) 12 −
0.67
−
1.76
0.43 − 0.19
Much worse (5) 2 −
1.00
−
13.71
11.71 − 0.28
LCL lower confidence limit, MCID minimal clinically important difference, mRSS
modified Rodnan Skin Score, SF-36 Short Form-36, SSc systemic sclerosis, UCL
upper confidence limit
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the mean mRSS MCID estimate for HAQ-DI improve-
ment was − 4.64 with an effect size of 0.48, and this was
similar to the group with no change in HAQ-DI (mean
change of − 4.8 and effect size of 0.50; Table 4). Using
the PtGA, the mean mRSS MCID estimate for PtGA im-
provement was − 5.12 with an effect size of 0.53, and
this was similar to the group with no change in PtGA
(mean change of − 5.16 and effect size of 0.54; Table 5).
mRSS MCID estimates for reported improvement in those
with lcSSc
For those participants with lcSSc, the mRSS MCID esti-
mates were small and within the measurement error of
the mRSS (Tables 3, 4, and 5). Specifically, the mRSS
MCID estimate was 0.67 for improvement on the SF-36
health transition question, − 1.58 for improvement in
HAQ-DI scores, and − 1.0 for improvement in PtGA
scores.
mRSS MCID estimates for reported worsening in the
cohort
On average, the mRSS improved in participants who cat-
egorized themselves as “somewhat worse” on health
transition, and using definitions of worsening in
HAQ-DI and PtGA (Table 3, 4, and 5). These trends
were also seen in those specifically with dcSSc.
Table 4 Estimation of MCID estimates in mRSS using HAQ-DI
anchor for all participants
HAQ-DI N Unadjusted mean Effect
sizeMean 95%
LCL
95%
UCL
Overall
Change ≤ − 0.48 38 −
6.11
−
8.29
−
3.92
− 0.57
− 0.14 ≥ change > − 0.48 (MCID
estimate for improvement)
34 −
3.56
− 6 −
1.12
− 0.33
− 0.14 < change < 0.14 108 −
2.55
−
3.47
−
1.62
− 0.24
0.14≤ change < 0.48 26 −
0.88
−
2.84
1.07 − 0.08
Change ≥ 0.48 37 −
1.03
−
3.14
1.09 − 0.10
Diffuse SSc
Change ≤ − 0.48 29 −
7.97
−
10.41
−
5.52
− 0.83
− 0.14 ≥ change > − 0.48 (MCID
estimate for improvement)
22 −
4.64
−
8.28
−
0.99
− 0.48
− 0.14 < change < 0.14 54 − 4.8 −
6.23
−
3.36
− 0.50
0.14≤ change < 0.48 16 −
1.69
−
4.88
1.5 − 0.18
Change ≥ 0.48 25 −
1.48
−
4.56
1.6 − 0.15
Limited SSc
Change ≤ − 0.48 9 −
0.11
− 2.3 2.08 − 0.03
− 0.14 ≥ change > − 0.48 (MCID
estimate for improvement)
12 −
1.58
−
3.74
0.57 − 0.44
− 0.14 < change < 0.14 54 − 0.3 −
1.15
0.56 − 0.08
0.14≤ change < 0.48 10 0.4 −
0.68
1.48 0.11
Change ≥ 0.48 12 −
0.08
−
1.99
1.82 − 0.02
HAQ-DI Health Assessment Questionnaire -Disability Index, LCL lower
confidence limit, MCID minimal clinically important difference, mRSS modified
Rodnan Skin Score, SSc systemic sclerosis, UCL upper confidence limit
Table 5 Estimation of MCID estimates in mRSS using Patient
Global Assessment anchor for all participants
Patient Global
Assessment
N Unadjusted mean Effect
sizeMean 95%
LCL
95%
UCL
Overall
Change ≤ − 50 8 −
3.75
−
7.69
0.19 −
0.35
−20 ≥ change > − 50 (MCID
estimate for improvement)
35 −
4.06
−
6.66
−
1.45
−
0.38
− 20 < change < 20 123 −
2.94
−
3.92
−
1.96
−
0.27
20≤ change < 50 23 −
0.17
−
2.71
2.36 −
0.02
Change ≥ 50 6 1.5 −
2.94
5.94 0.14
Diffuse SSc
Change ≤ − 50 5 −
5.60
−
11.85
0.65 −
0.58
−20 ≥ change > − 50 (MCID
estimate for improvement)
26 −
5.12
−
8.48
−
1.75
−
0.53
− 20 < change < 20 69 −
5.16
−
6.57
−
3.74
−
0.54
20≤ change < 50 16 −
0.56
−
4.25
3.12 −
0.06
Change ≥ 50 2 6.50 −
25.27
38.27 0.68
Limited SSc
Change ≤ − 50 3 −
0.67
−
5.84
4.50 −
0.19
− 20 ≥ change > − 50 (MCID
estimate for improvement)
9 −
1.00
−
3.72
1.72 −
0.28
− 20 < change < 20 54 −
0.11
−
0.98
0.76 −
0.03
20≤ change < 50 7 0.71 −
1.40
2.83 0.20
Change ≥ 50 4 −
1.00
−
2.30
0.30 −
0.28
LCL lower confidence limit, MCID minimal clinically important difference, mRSS
modified Rodnan Skin Score, SSc systemic sclerosis, UCL upper confidence limit
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Relationship between the mRSS MCID estimates, patient-
reported outcomes, and musculoskeletal examination
We explored whether the participants whose mRSS
scores improved by ≥ MCID over 12months had parallel
changes in patient-reported outcome scores (Table 6).
We used an improvement of > 3 and 4 units of the
mRSS for the overall group and > 5 units of the mRSS
for those with dcSSc. For the participants who met these
mRSS MCID improvement criteria, they also had signifi-
cantly greater improvements for the SF-36 physical com-
ponent summary and the TDI compared to those whose
mRSS changes did not meet the MCID estimates (p <
0.05 for all comparisons), for both the overall group and
for those with dcSSc. For those with dcSSc, a greater
proportion of participants who met the mRSS MCID cri-
teria had an improvement in their small and large joint
contractures compared to those who did not meet the
MCID improvement criteria (p = 0.008).
Discussion
The mRSS is a surrogate of skin and internal organ in-
volvement in SSc and is feasible, reliable, valid, and sen-
sitive to change in multicenter clinical trials [2]. Since
the mRSS serves as the primary outcome measure in re-
cent clinical trials, it is important to define which
changes in the mRSS between two groups are clinically
meaningful (not just statistically significant). Addition-
ally, for the clinician, the MCID provides information on
treatment response and can help guide treatment. Our
data suggest that an improvement of 3–4 units in all SSc
patients (an improvement of 20–27% from the baseline
score) and an improvement of 5 units in dcSSc patients
(an improvement of 24% from baseline scores) are ap-
propriate MCID estimates.
Our data align with the mRSS MCID estimates from
the DPenicillamine trial (based on physician report),
where an improvement of 3.5–5.3 units was considered
the MCID [5]. Another study including the physician
consensus exercise also defined an improvement of 3.0–
7.5 units as the mRSS MCID estimates for improvement
[21]. Additionally, improvements of > 5 units and ≥ 25%
have recently been considered clinically important esti-
mates for the mRSS in dcSSc [22]. Thus, our findings
are very similar to published estimates. In addition, our
MCID estimates are associated with statistically signifi-
cant changes in the SF-36 physical component summary
and TDI as well as improvement in small and large joint
contractures, suggesting that these MCID estimates
translate into how a patient feels and functions [23].
MCID estimates are calculated at a group level and
should not be confused with change in a measure in an in-
dividual patient. At an individual level, a larger change is
required to be considered a statistically significant change,
and it is influenced by both measurement error and
normal biologic variability over time [4]. It may also be in-
fluenced by the severity of disease and skin involvement.
Our data highlight a few important things about asses-
sing the MCID estimates. First, despite the large number
of participants in the two trials, the lack of appropriate
correlations between the anchors and the mRSS indicate
uncertainty in the point estimates. This is highlighted by
the similar mean changes in the mRSS for both the
MCID improved and no change groups for those with
dcSSc. Second, using the patient anchors of SF-36 health
transition, HAQ-DI, and PtGA, patients who worsened
on these anchors still had, on average, an overall im-
provement in the mRSS (with wide CIs that crossed 1).
Although this seems surprising, this is likely due to the
poor correlation coefficients between the anchors and
the mRSS, as the SF-36 health transition question and
the PtGA survey assess overall change in health (beyond
improvement in skin) and the HAQ-DI asks about daily
functional activities [15]. In previous analyses from a
dcSSc cohort, the mRSS had a larger correlation with
the physician global assessment compared to the PtGA
[15]. Incorporating anchors that focus on change in skin
involvement and its impact on function and other daily
activities may be more appropriate and should be con-
sidered in future trials. Third, as expected, those with
lcSSc had minimal change in the mRSS during the two
SSc trials. In our analyses, the change in the mRSS for
those with lcSSc was ≤ 1.0 units in a majority of the
subgroups.
Our study has many strengths. We used prospective
data from two large SSc randomized controlled trials
(SLS-I and SLS-II) to determine MCID estimates. Al-
though the mRSS was not the primary outcome measure,
it was captured by expert centers in the USA and assessed
by the same investigator for a given patient. Second, we
have validated the MCID estimates for the mRSS using
patient-driven anchors; all previous estimates were based
on physician anchors [21] or consensus agreement. Our
effect size in this analysis for the MCID groups (range of
0.48–0.53) is very similar to the estimates provided by
Khanna et al. ([5] effect sizes for the MCID group were
between 0.40–0.66). Third, MCID estimates are an ap-
proximation, and experts have suggested using multiple
anchors to define a range for these estimates [4] so we in-
cluded three anchors in the current analysis. Fourth, our
analysis provided MCID estimates that correspond to
patient-reported outcome changes over time, supporting
the validity of these estimates.
Our study is not without limitations. First, the analysis
was post hoc rather than a priori. Second, the correl-
ation between the anchors and the mRSS was less than
the proposed cutoff point of 0.30, adding to the uncer-
tainty of these estimates. For example, the relationship
between the SF-36 health transition and PtGA anchors
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versus the mRSS outcome may have been influenced by
changes in variables unrelated to the skin, including
lungs, gastrointestinal involvement, and other disease
manifestations. Further analyses of ongoing clinical trials
should explore other anchors that focus on skin involve-
ment rather than global disease and that have better as-
sociations with the mRSS.
Conclusion
We report patient-based MCID estimates for the mRSS
using data from two large randomized controlled trials.
These mRSS MCID estimates can be used for interpret-
ation of ongoing clinical trials in SSc and interstitial lung
disease, and for sample size estimation in future trials.
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